In addition, a sustained activation of STAT3 occurs in more than 50% of NSCLC patients [129,130], and its increased expression leads to low-grade tumor differentiation, lymph node metastasis, clinical stage progression, and drug resistance [131,132,133]. This evidence concerns the gene STAT3 and non-small cell lung carcinoma.